ERBB2 and breast cancer: In this prospective study, we demonstrate proof‐of‐concept that longitudinal z‐score trajectories rather than single time point measurements may harbor important dynamic information on the development of disease progression in HR+HER2− breast cancer patients undergoing CDK4/6 inhibitor treatment.